Serologic Response to Coronavirus Disease 2019 (COVID-19) Vaccination in Patients With Immune-Mediated Inflammatory Diseases: A Systematic Review and Meta-analysis

Review Rheumatology

Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis

Shintaro Akiyama et al.

Summary: Patients with autoimmune diseases have a higher risk of COVID-19, primarily due to glucocorticoid use. Monotherapy with b/tsDMARDs is associated with a lower risk of hospitalisation and death.

ANNALS OF THE RHEUMATIC DISEASES (2021)

Add to Collection

Article Rheumatology

The effect of methotrexate and targeted immunosuppression on humoral and cellular immune responses to the COVID-19 vaccine BNT162b2: a cohort study

Satveer K. Mahil et al.

Summary: Patients receiving methotrexate may have impaired humoral immunity to a single dose of the BNT162b2 vaccine, but not those receiving targeted biologics. Cellular immune responses are preserved in all groups. Real-world pharmacovigilance studies are needed to determine the clinical effectiveness of these findings.

LANCET RHEUMATOLOGY (2021)

Add to Collection

Article Health Care Sciences & Services

Preprint manuscripts and servers in the era of coronavirus disease 2019

Shayan Nabavi Nouri et al.

Summary: Preprint publishing has become increasingly important in health sciences research, especially during the COVID-19 pandemic. While posting manuscripts on preprint servers can facilitate rapid communication of findings, there is also a risk of disseminating erroneous data.

JOURNAL OF EVALUATION IN CLINICAL PRACTICE (2021)

Add to Collection

Editorial Material Gastroenterology & Hepatology

Humoral Immune Response to Messenger RNA COVID-19 Vaccines Among Patients With Inflammatory Bowel Disease

Michael D. Kappelman et al.

GASTROENTEROLOGY (2021)

Add to Collection

Letter Dermatology

COVID-19 vaccination and patients with psoriasis under biologics: real-life evidence on safety and effectiveness from Italian vaccinated healthcare workers

G. Damiani et al.

CLINICAL AND EXPERIMENTAL DERMATOLOGY (2021)

Add to Collection

Letter Rheumatology

Antibody response to a single dose of SARS-CoV-2 mRNA vaccine in patients with rheumatic and musculoskeletal diseases

Brian J. Boyarsky et al.

ANNALS OF THE RHEUMATIC DISEASES (2021)

Add to Collection

Article Rheumatology

SARS-CoV-2 vaccination responses in untreated, conventionally treated and anticytokine-treated patients with immune-mediated inflammatory diseases

David Simon et al.

Summary: Immune response against SARS-CoV-2 is delayed and reduced in patients with immune-mediated inflammatory diseases, regardless of treatment.

ANNALS OF THE RHEUMATIC DISEASES (2021)

Add to Collection

Letter Rheumatology

Rituximab, but not other antirheumatic therapies, is associated with impaired serological response to SARS-CoV-2 vaccination in patients with rheumatic diseases

Robert Spiera et al.

ANNALS OF THE RHEUMATIC DISEASES (2021)

Add to Collection

Article Rheumatology

Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort

Ulf M. Geisen et al.

Summary: In this study, the efficacy and safety of anti-SARS-CoV-2 mRNA vaccines in immunosuppressed patients were compared with healthy controls. The results showed that all study participants developed antibodies, with lower IgG titres in patients compared to controls. Side effects were minimal and no disease flares were observed, demonstrating the efficiency and safety of mRNA vaccines in this cohort despite its small size.

ANNALS OF THE RHEUMATIC DISEASES (2021)

Add to Collection

Letter Dermatology

Antibody responses to single-dose SARS-CoV-2 vaccination in patients receiving immunomodulators for immune-mediated inflammatory disease

A. Al-Janabi et al.

BRITISH JOURNAL OF DERMATOLOGY (2021)

Add to Collection

Editorial Material Gastroenterology & Hepatology

Serologic Response to Messenger RNA Coronavirus Disease 2019 Vaccines in Inflammatory Bowel Disease Patients Receiving Biologic Therapies

Serre-Yu Wong et al.

GASTROENTEROLOGY (2021)

Add to Collection

Article Gastroenterology & Hepatology

Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD

Nicholas A. Kennedy et al.

Summary: Infliximab treatment in patients with inflammatory bowel disease results in attenuated serological responses to a single dose of the SARS-CoV-2 vaccine. Delayed second dosing should be avoided in these patients, as vaccination after SARS-CoV-2 infection or a second dose leads to seroconversion in most individuals.

GUT (2021)

Add to Collection

Article Gastroenterology & Hepatology

Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab

Nicholas A. Kennedy et al.

Summary: The study found that patients with inflammatory bowel disease treated with infliximab had attenuated serological responses to SARS-CoV-2 infection. Additionally, the serological response to SARS-CoV-2 infection in the infliximab-treated group was further blunted by concomitant use of immunomodulators.

GUT (2021)

Add to Collection

Review Gastroenterology & Hepatology

SARS-CoV-2 Vaccination in IBD: Past Lessons, Current Evidence, and Future Challenges

Judith Wellens et al.

Summary: Patients with inflammatory bowel diseases (IBD) have been considered high-risk for COVID-19 infection and complications since the start of the pandemic. However, they were excluded from clinical phase III vaccine trials, leading to challenges in assessing the effectiveness of new vaccines. Adapted vaccination strategies may be needed for some IBD patients to optimize immune response. Therefore, further research is needed to develop tailored vaccination plans for IBD patients.

JOURNAL OF CROHNS & COLITIS (2021)

Add to Collection

Article Rheumatology

Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry

Jeffrey A. Sparks et al.

Summary: This study investigated the baseline use of biologic or targeted synthetic disease-modifying antirheumatic drugs and COVID-19 outcomes in patients with rheumatoid arthritis. The results showed that patients treated with rituximab or Janus kinase inhibitors were associated with worse COVID-19 severity, emphasizing the need for prioritizing risk mitigation strategies for these individuals.

ANNALS OF THE RHEUMATIC DISEASES (2021)

Add to Collection

Article Rheumatology

Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study

Victoria Furer et al.

Summary: Vaccination with mRNA BNT162b2 vaccine showed reduced immunogenicity in patients with AIIRD compared to the general population, with risk factors including older age and treatment with glucocorticoids, rituximab, mycophenolate mofetil (MMF), and abatacept. However, most patients maintained stable disease activity post-vaccination.

ANNALS OF THE RHEUMATIC DISEASES (2021)

Add to Collection

Article Rheumatology

Disease activity and humoral response in patients with inflammatory rheumatic diseases after two doses of the Pfizer mRNA vaccine against SARS-CoV-2

Yolanda Braun-Moscovici et al.

Summary: The vast majority of patients with inflammatory rheumatic diseases developed a significant humoral response following the administration of the second dose of the Pfizer mRNA vaccine against SARS-CoV-2 virus. Only minor side effects were reported and no apparent impact on IRD activity was noted.

ANNALS OF THE RHEUMATIC DISEASES (2021)

Add to Collection

Article Rheumatology

SARS-CoV-2 vaccination in rituximab-treated patients: B cells promote humoral immune responses in the presence of T-cell-mediated immunity

Daniel Mrak et al.

Summary: The study found that RTX-treated patients can develop SARS-CoV-2-specific antibodies after vaccination, but only if peripheral B cells at least partially repopulate. Additionally, more than half of the vaccinated patients developed SARS-CoV-2-specific T cells, which may provide protective effects regardless of humoral immune responses.

ANNALS OF THE RHEUMATIC DISEASES (2021)

Add to Collection

Letter Rheumatology

High antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in patients with rheumatic and musculoskeletal diseases

Jake A. Ruddy et al.

ANNALS OF THE RHEUMATIC DISEASES (2021)

Add to Collection

Article Rheumatology

Methotrexate hampers immunogenicity to BNT162b2 mRNA COVID-19 vaccine in immune-mediated inflammatory disease

Rebecca H. Haberman et al.

Summary: The study found that patients with immune-mediated inflammatory diseases (IMIDs) on methotrexate treatment showed impaired humoral and cellular immune response to COVID-19 mRNA vaccines, while healthy subjects and IMID patients on biologic treatments demonstrated strong antibody responses. These results suggest that different strategies may need to be explored to enhance immunization efficacy for IMID patients on methotrexate treatment.

ANNALS OF THE RHEUMATIC DISEASES (2021)

Add to Collection

Article Rheumatology

Antibody response to inactivated COVID-19 vaccine (CoronaVac) in immune-mediated diseases: a controlled study among hospital workers and elderly

Emire Seyahi et al.

Summary: Patients with immune-mediated diseases had lower antibody response to the inactivated COVID-19 vaccine compared to healthy controls, especially those using immunosuppressive or immune-modulating drugs. Older age was also associated with lower antibody titers in both patient and control populations. Further studies are needed to determine if booster doses are necessary for these individuals.

RHEUMATOLOGY INTERNATIONAL (2021)

Add to Collection

Letter Rheumatology

Correspondence on SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response by Bonelli et al

Sarah H. Chung et al.

ANNALS OF THE RHEUMATIC DISEASES (2021)

Add to Collection

Letter Urology & Nephrology

Low rates of humoral response to BNT162b2 SARS-CoV-2 vaccination in patients with immune-mediated kidney diseases treated with rituximab

Nathalie Demoulin et al.

CLINICAL KIDNEY JOURNAL (2021)

Add to Collection

Article Rheumatology

Impaired Antibody Response to the BNT162b2 Messenger RNA Coronavirus Disease 2019 Vaccine in Patients With Systemic Lupus Erythematosus and Rheumatoid Arthritis

Christian Ammitzboll et al.

Summary: The study investigated the antibody response to the Pfizer-BioNTech BNT162b2 vaccine in rheumatic disease patients receiving immunosuppressive therapy, finding that 23% of patients could not mount a detectable serological response. Special attention is needed for patients receiving B cell-depleting therapy.

ACR OPEN RHEUMATOLOGY (2021)

Add to Collection

Article Medicine, General & Internal